Recommendations for the Use of Everolimus (Certican) in Heart Transplantation: Results From the Second German–Austrian Certican Consensus Conference
Authors:
- Markus RothenburgerMRMarkus Rothenburger
- Andreas ZuckermannAZAndreas Zuckermann
- Christoph BaraCBChristoph Bara
- Manfred HummelMHManfred Hummel
- Martin StrüberMSMartin Strüber
- Stephan HirtSHStephan Hirt
- Hans LehmkuhlHLHans Lehmkuhl
- 1 April 2007
- journal article
- practice guideline
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 26 (4) , 305-311
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Everolimus versus Mycophenolate Mofetil in the Prevention of Rejection in De Novo Renal Transplant Recipients: A 3-Year Randomized, Multicenter, Phase III StudyTransplantation, 2005
- Editorial Comment: Reduction in Calcineurin Inhibitor Exposure and Maintenance of Effective Immunosuppression: Clinical Experience with Everolimus (Certican)Transplantation, 2005
- Three‐Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant PatientsAmerican Journal of Transplantation, 2005
- Graft Function, Cardiovascular Risk Factors, and Sex Hormones in Renal Transplant Recipients on an Immunosuppressive Regimen of Everolimus, Reduced Dose of Cyclosporine, and BasiliximabTransplantation Proceedings, 2005
- Recommendations for Use of Certican® (Everolimus) After Heart Transplantation: Results From a German and Austrian Consensus ConferenceThe Journal of Heart and Lung Transplantation, 2005
- Therapeutic Drug Monitoring for Everolimus in Heart Transplant Recipients Based on Exposure–Effect ModelingAmerican Journal of Transplantation, 2004
- Everolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6-Month Safety and Efficacy Results of Two Randomized StudiesAmerican Journal of Transplantation, 2004
- EverolimusDrugs, 2004
- Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant RecipientsNew England Journal of Medicine, 2003
- High‐throughput semi‐automated 96‐well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD 001) and cyclosporin a (CsA) in whole bloodRapid Communications in Mass Spectrometry, 2001